Article Text

PDF

Danazol in non-splenectomized patients with refractory idiopathic thrombocytopenic purpura.
  1. D. Z. Edelmann,
  2. B. Knobel,
  3. I. Virag,
  4. D. Meytes
  1. Department of Hematology, Edith Wolfson Medical Center, Holon, Israel.

    Abstract

    Seven non-splenectomized patients with chronic refractory idiopathic thrombocytopenic purpura were treated with danazol 800 mg daily. All were glucocorticoid failures and four were refractory to all additional previous therapy. Five patients benefited from danazol and in two sustained normal platelet counts, for over 44 and 51 months, were observed. We conclude that danazol is useful for long term management of otherwise refractory idiopathic thrombocytopenic purpura. The advantage of danazol over splenectomy as a first line treatment in steroid failure is suggested.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.